Decided to dispose of inventories related to the in-house brand \u201c\u22524.7\u201d, expecting to record an extraordinary loss of 12 million yen. There is a possibility of additional losses related to the settlement of OEM transactions in the liquidation of Axel Medica, and the impact on consolidated and non-consolidated results for the fiscal year ending September 2026 is under review. Obtaining a cosmetics manufacturing and marketing license is not foreseeable, making sale or monetization difficult.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3624","jir_company_name":"Axel Mark Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/3624-20260930-01.pdf","jir_short_summary":"Decided to dispose of inventories related to the in-house brand \u201c\u22524.7\u201d, expecting to record an extraordinary loss of 12 million yen. There is a possibility of additional losses related to the settlement of OEM transactions in the liquidation of Axel Medica, and the impact on consolidated and non-consolidated results for the fiscal year ending September 2026 is under review. Obtaining a cosmetics manufacturing and marketing license is not foreseeable, making sale or monetization difficult.","jir_summary":"### Summary of the News\nAxel Mark Inc. decided to dispose of inventories that were inherited from its wholly owned subsidiary Axel Medica, as they can no longer be sold. Accordingly, it expects to record an extraordinary loss of 12 million yen in the fiscal year ending September 2026. In addition, it has disclosed the possibility of additional losses related to the settlement of OEM transactions in connection with the liquidation of Axel Medica.\n\n### Outlook and Impact\nIt is currently difficult to newly obtain a cosmetics manufacturing and marketing license, and unless such a license is acquired, selling or transferring the inventories to third parties will be difficult. For some OEM transactions there is a possibility of requests for refund of advance payments or the occurrence of additional liabilities; the impact on results for the fiscal year ending September 2026 is currently being examined. The timing for resuming the Beauty & Wellness business is TBD.","jir_financial_highlights":"Inventory Valuation Loss: 12 million yen (Unknown)\nUnderlying Assets: Cosmetic products and raw materials related to the in-house brand \u201c\u22524.7\u201d (Unknown)","jir_category":"","jir_hashtags":"#AxelMark, #DisclosureUpdate, #InventoryDisposal","jir_key_figures":"Inventory Valuation Loss: 12 million yen\nTarget Assets: Cosmetic products and raw materials related to the in-house brand \u201c\u22524.7\u201d\nHolding Company: Axel Mark Inc.","jir_meta_title":"Axel Mark Inc. \u2014 Notice of Extraordinary Loss from Inventory Disposal | Fiscal Year Ending September 2026","jir_meta_description":"Axel Mark Inc. will dispose of inventories for its in-house brand \u201c\u22524.7\u201d, expecting to record an extraordinary loss of 12 million yen and disclosing the possibility of additional losses. The prospect of obtaining cosmetics permits is unclear; the impact on future results is being assessed.","jir_og_title":"Axel Mark Inc. \u2014 Notice of Extraordinary Loss from Inventory Disposal","jir_og_description":"Axel Mark Inc. will dispose of inventories for its in-house brand and expects to record an extraordinary loss of 12 million yen, with the possibility of additional losses. Permitting prospects are uncertain and the company is monitoring the impact on results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":61293,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-124709","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n